New lung cancer drug shows dramatic results for shrinking tumors

Jun 22, 2010

Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.

"The results of the first two trials have been very encouraging," said Lyudmila Bazhenova, MD, assistant clinical professor at UC San Diego School of Medicine and a member of the Moores UCSD Cancer Center. "The Phase III clinical trials will be critical in determining if this drug goes to market."

According to a preliminary study presented at the 2010 meeting of the American Society of Clinical Oncology, Phase I/II demonstrated that 57% of patients had their tumors reduced and at eight weeks of the treatment, 87% showed disease stabilization.

In some patients with non-small cell (NSCLC), the anaplastic lymphoma kinase (ALK) gene may move and fuse with another gene, EML4. The resultant fusion produces an enzyme that promotes lung cancer cell growth. This fusion happens in approximately four percent of NSCLC patients. The chances of a patient having the increases if they have the adenocarcinoma subtype of lung cancer, or are non-smokers or former light smokers, among other characteristics. Those patients have an approximate 20% chance of having this mutation. Crizotinib inhibits the enzyme, allowing the to die off.

The Phase III clinical trial will compare crizotinib with standard-of-care chemotherapy in the treatment of ALK-positive recurrent NSCLC. Through a randomized selection process, patients will either be treated with chemotherapy or crizotinib. If the patients who are given the chemotherapy do not respond to treatment, they will be given crizotinib at the end of the trial.

Explore further: Synthetic lethality offers a new approach to kill tumor cells

add to favorites email to friend print save as pdf

Related Stories

Pfizer lung cancer drug promising in early tests

Jun 05, 2010

(AP) -- It's way too soon to declare success, but an experimental drug for lung cancer patients with a certain gene showed extraordinary promise in early testing, doctors reported at a cancer conference on Saturday.

Best care for the oldest lung cancer patients

Apr 29, 2010

Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce. Now Italian oncologists are conducting ...

Recommended for you

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.